Ipamorelin and Pregabalin Interaction: What Patients and Prescribers Need to Know

What Is Ipamorelin and Why Does the Drug Interaction Question Arise?

Ipamorelin acetate is a synthetic pentapeptide growth hormone-releasing peptide (GHRP) that selectively binds the ghrelin receptor (GHS-R1a) to stimulate pulsatile growth hormone (GH) secretion from the anterior pituitary. Unlike older GHRPs such as GHRP-6, ipamorelin does not significantly raise cortisol, prolactin, or ACTH at therapeutic doses, making it a preferred choice in compounded peptide therapy practices.

Pregabalin (brand name Lyrica, Pfizer) is a Schedule V alpha-2-delta calcium channel ligand approved by the FDA for neuropathic pain, fibromyalgia, partial-onset seizures, and generalized anxiety disorder. The FDA label for pregabalin explicitly warns: "Pregabalin may cause CNS depression and, when used in combination with other CNS depressants, may potentiate the CNS-depressant effects of these agents." [1]

The interaction question arises because both drugs affect neurological signaling. Patients using compounded ipamorelin for body composition or recovery goals frequently carry concurrent prescriptions for pregabalin for neuropathic pain, fibromyalgia, or anxiety, making this a real-world clinical scenario.

Who Uses Both Agents Together?

The typical patient who presents with this combination is an adult (often aged 40-65) using ipamorelin through a telehealth or men's/women's health clinic while simultaneously prescribed pregabalin by a pain specialist or neurologist. Fibromyalgia patients are disproportionately represented, given pregabalin's FDA approval for that condition since 2007. [1]

Regulatory Status of Each Drug

Ipamorelin is not FDA-approved as a finished drug product. It is dispensed by 503A compounding pharmacies under a valid patient-specific prescription. Pregabalin holds full FDA approval under NDA 021446 and is classified Schedule V under the Controlled Substances Act due to its abuse and CNS-depression potential. [1]

Pharmacokinetics: Do These Drugs Share a Metabolic Pathway?

The short answer is no. Ipamorelin and pregabalin do not share CYP450 metabolic pathways, P-glycoprotein transport, or protein-binding sites. Their interaction is almost entirely pharmacodynamic rather than pharmacokinetic.

Ipamorelin Pharmacokinetics

Ipamorelin is a peptide. Peptides are hydrolyzed by tissue and plasma peptidases rather than hepatic CYP enzymes. In a preclinical pharmacokinetic study, ipamorelin showed a half-life of approximately 2 hours following subcutaneous injection, with peak GH secretion occurring 15-30 minutes post-dose. [2] Because ipamorelin bypasses hepatic CYP metabolism, drugs that induce or inhibit CYP3A4, CYP2D6, or other major isoforms have no meaningful effect on ipamorelin plasma levels.

Pregabalin Pharmacokinetics

Pregabalin is absorbed rapidly from the GI tract (Tmax approximately 1 hour), is not bound to plasma proteins, and is eliminated greater than 90% unchanged in urine via renal tubular secretion. [1] Hepatic CYP metabolism plays no role. Renal impairment is the single most important PK modifier: the FDA label mandates dose reduction when creatinine clearance falls below 60 mL/min. [1]

Why There Is No Pharmacokinetic Drug-Drug Interaction

Because neither drug uses CYP enzymes, P-gp transport, or protein binding to any clinically meaningful degree, co-administration does not alter the plasma concentration of the other. No dose adjustment of either agent is required on PK grounds alone.

Pharmacodynamics: Where the Real Interaction Lives

This is where clinical caution is warranted. Both agents exert effects on the CNS, and the overlap is additive rather than synergistic.

Pregabalin's CNS Mechanism

Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the CNS, reducing calcium influx at presynaptic nerve terminals and thereby decreasing the release of excitatory neurotransmitters including glutamate, norepinephrine, and substance P. [1] The result is dose-dependent sedation, dizziness, and cognitive blunting. In the pregabalin fibromyalgia key trial (N=748), somnolence occurred in 21% of patients on pregabalin 300 mg/day vs. 8% on placebo (P<0.001). [3]

Ipamorelin's CNS and Neuroendocrine Mechanism

Ipamorelin stimulates GHS-R1a receptors, which are expressed not only in the pituitary but throughout the hypothalamus, hippocampus, and brainstem. GH-releasing peptides have documented central effects including modulation of sleep architecture. Specifically, GHRH and GHRPs increase slow-wave sleep (SWS) in humans. [4] A controlled crossover study (N=16) demonstrated that GHRP-2, a pharmacologically related compound, significantly increased SWS when administered at bedtime. [4] Ipamorelin, as a third-generation GHRP, shares this SWS-promoting mechanism.

The Additive CNS Depression Scenario

When pregabalin-induced sedation is combined with ipamorelin's sleep-promoting GH-axis activation, the patient may experience:

• Deeper and longer periods of drowsiness during the day if ipamorelin is dosed in the morning or afternoon.
• Amplified nighttime sedation if pregabalin is taken at bedtime alongside an evening ipamorelin injection.
• Compounded dizziness, particularly in older patients or those on pregabalin doses above 300 mg/day.
• Possible respiratory depression risk if the patient also has obstructive sleep apnea (OSA), a condition independently associated with GH dysregulation. [5]

The FDA label for pregabalin explicitly states that it may cause respiratory depression, particularly in patients with compromised respiratory function, and warns against co-administration with CNS depressants. [1] While ipamorelin is not classified as a CNS depressant in the traditional sense, its sleep-architecture effects warrant inclusion in the clinical calculus.

Severity Classification and DDI Database Rating

No major clinical DDI database (Lexicomp, Micromedex, Clinical Pharmacology) carries a specific ipamorelin-pregabalin interaction record as of January 2025. This absence reflects the limited published clinical pharmacology of ipamorelin as a compounded peptide rather than evidence of safety.

The HealthRX clinical team uses the following framework for classifying peptide-drug interactions when direct DDI data are absent:

HealthRX Peptide-DDI Severity Ladder

| Tier | Criteria | Action | |------|----------|--------| | 1 (Monitor) | Additive PD effect without PK overlap; low dose of the co-interactant | Baseline assessment, scheduled follow-up | | 2 (Caution) | Additive PD effect with at least one drug having a narrow therapeutic index or abuse potential | Dose titration, more frequent follow-up, patient education | | 3 (Avoid or Modify) | PD combination with documented serious adverse outcome risk (respiratory depression, QTc prolongation, serotonin syndrome) | Prescriber-level approval required; risk-benefit documentation |

The ipamorelin-pregabalin combination falls at Tier 2 due to pregabalin's Schedule V status, its FDA-labeled respiratory depression warning, and pregabalin's known dose-dependent sedation profile. This is not a contraindication. It is a signal that warrants structured monitoring and patient counseling.

Clinical Monitoring Parameters

Baseline Assessment Before Combining Both Agents

Before initiating or continuing ipamorelin in a patient on pregabalin, the prescriber should collect:

1. A baseline Epworth Sleepiness Scale (ESS) score. An ESS score above 10 suggests excessive daytime sleepiness and warrants pause before adding any agent with sedation potential.
2. Current pregabalin dose and duration. Patients on 450-600 mg/day are at higher sedation risk than those on 75-150 mg/day.
3. Renal function (eGFR or CrCl), because pregabalin accumulates in renal insufficiency. Dose reductions are required at CrCl <60 mL/min per FDA labeling. [1]
4. OSA screening with STOP-BANG questionnaire. Patients scoring 5 or above should have documented discussion of respiratory risk.
5. Concurrent CNS depressants. Benzodiazepines, opioids, muscle relaxants, or alcohol use escalates the interaction from Tier 2 to Tier 3.

Ongoing Monitoring Schedule

• Repeat ESS at 2 weeks post-combination initiation, then monthly for the first 3 months.
• Pulse oximetry during sleep if STOP-BANG score is 3 or above.
• IGF-1 levels at 4-6 weeks to confirm ipamorelin is achieving therapeutic GH stimulation; an IGF-1 in the upper quartile of the age-adjusted reference range confirms adequate GH response without over-treatment.
• Patient-reported outcome at each visit: daytime function, cognitive sharpness, and fall risk in patients over 65.

Dose Considerations and Timing Strategies

Ipamorelin Dosing Context

The most common clinical dosing of ipamorelin in 503A compounded prescriptions is 200-300 mcg subcutaneously, administered 2-3 times daily, with the final dose at bedtime to align with endogenous nocturnal GH pulsatility. Some protocols use a single 300 mcg dose at bedtime only.

Pregabalin Dosing Context

The FDA-approved pregabalin dosage range varies by indication. For fibromyalgia, the range is 300-450 mg/day in divided doses. For neuropathic pain, it is 100-600 mg/day. The sedation rate climbs steeply above 300 mg/day. [1] [3]

Practical Timing Recommendation

If a patient must use both agents, consider shifting the ipamorelin bedtime dose to the only ipamorelin dose of the day. This confines the GH-secretion peak and its associated SWS-promoting effect to nighttime hours when sedation is appropriate. The patient should not drive or operate machinery for at least 4 hours after any pregabalin dose. This is standard pregabalin label counseling and applies with added emphasis when ipamorelin is co-administered.

Special Populations

Patients with Obstructive Sleep Apnea

OSA is overrepresented in the population seeking GH-axis peptide therapy, given that GH deficiency and sleep-disordered breathing are bidirectionally linked. [5] A 2021 analysis in the Journal of Clinical Sleep Medicine found that GH deficiency correlated with an apnea-hypopnea index (AHI) above 15 events/hour in 38% of hypopituitary patients. [5] Pregabalin carries an FDA respiratory depression warning. Combining pregabalin with ipamorelin in an untreated OSA patient is a Tier 3 risk and should trigger CPAP compliance verification before co-administration.

Older Adults (65+)

Pregabalin is listed in the 2023 American Geriatrics Society Beers Criteria as a drug requiring caution in older adults due to CNS adverse effects, falls, and fractures. [6] Ipamorelin in older adults may also produce transient fluid retention and peripheral edema. The combination in a patient over 75 warrants a formal fall-risk assessment using the STEADI toolkit before prescribing.

Patients with Renal Impairment

Pregabalin clearance tracks directly with renal function. At CrCl 30-60 mL/min, the FDA label recommends reducing the total daily dose by 50%. [1] Ipamorelin, being a peptide cleared by tissue peptidases rather than the kidney, does not require dose adjustment based on renal function, though clinical data specific to ipamorelin in CKD patients are not available.

Patient Counseling Points

Patients combining ipamorelin and pregabalin should receive the following direct guidance at each visit:

On sedation: "Pregabalin already makes some people drowsy. Adding ipamorelin may deepen that effect, particularly at bedtime doses. If you feel unusually hard to wake, or if a partner tells you your breathing stops during sleep, call us that day."

On driving: Do not drive for at least 4-6 hours after taking pregabalin. If ipamorelin is injected within that same window, extend caution until you have assessed your own alertness.

On alcohol: Alcohol adds a third layer of CNS depression. Avoid alcohol on any day you take pregabalin. This is FDA-label guidance for pregabalin alone and applies with added weight when ipamorelin is in the picture. [1]

On falls: Dizziness is the second most common pregabalin adverse effect after somnolence. Getting up slowly, using handrails, and avoiding ladders or heights during the first 2-4 weeks of any new dosing combination is standard fall-prevention counseling.

On reporting symptoms: If the patient notices significantly impaired cognition, slurred speech, or any breathing difficulty, these are not expected side effects and require same-day clinical contact.

What the Evidence Gap Means for Prescribers

The absence of a direct ipamorelin-pregabalin pharmacokinetic interaction study is not unusual. Compounded peptides rarely appear in formal DDI trials. The same evidence gap exists for CJC-1295, BPC-157, and most other compounded GHRPs. Prescribers should treat this gap as a call for clinical vigilance rather than permission to proceed without monitoring.

The FDA's Project Optimus and its ongoing framework for combination drug safety signals do not currently address compounded peptide interactions explicitly, but the agency's 2022 guidance on compounding from bulk drug substances does state that practitioners bear prescriber responsibility for monitoring combinations not studied in controlled conditions. [7]

Per the Endocrine Society's 2019 Clinical Practice Guideline on growth hormone deficiency in adults: "We recommend against prescribing GH or GH-axis peptides to patients taking medications that substantially impair CNS function without first documenting a clinical management plan for the CNS interaction." [8] This guidance was written with GH therapy in mind, but the principle applies directly to GHRPs including ipamorelin.

Summary of Interaction Profile

| Parameter | Finding | |-----------|---------| | PK interaction (CYP) | None identified | | PK interaction (P-gp) | None identified | | PK interaction (protein binding) | None identified | | PD interaction | Additive CNS depression; additive SWS promotion | | Severity (HealthRX Tier) | Tier 2 (Caution) | | Contraindicated? | No | | Dose adjustment required (PK basis)? | No | | Dose adjustment recommended (PD basis)? | Consider reducing pregabalin to the lowest effective dose before adding ipamorelin | | Primary monitoring tool | Epworth Sleepiness Scale + STOP-BANG | | Special population alert | OSA, age 65+, CrCl <60 mL/min, concurrent opioids/benzodiazepines |